Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd is a supplier of custom antibodies to the research industry and industrial community. The company has aggregated its operations into one reportable segment, Antibody Production, and Related Services. It operates in three principal geographical areas - the United States of America, Canada, Europe, and others. The majority of its revenue is derived from the United... see more

NDAQ:IPA - Post Discussion

Immunoprecise Antibodies Ltd > IPA management lost their tongue
View:
Post by GoldenArm on Feb 17, 2021 9:42am

IPA management lost their tongue

Wow the long silence is not helping. Maybe they are so busy that investors are not important right now. Anyways it is oversold again so back in I go. Made a few hundred the last time it dipped below $18.
Comment by GoldenArm on Feb 18, 2021 4:16pm
2 for 2. Bought when it went below 17.50 yesterday and sold at the end of the day today. Maybe management should stay quiet so I can trade IPA. Still own shares as an investor.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities